Emerging protein delivery methods

Current Opinion in Biotechnology

Volumn 12, Issue 2, 2001, Pages 212-219

  Cleland, Jeffrey L ^a   Daugherty, Ann ^a   Mrsny, Randall ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INJECTION; PRIORITY JOURNAL; PROTEIN QUALITY; REVIEW;

EID: 0035313228     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(00)00202-0     Document Type: Review

References (52)

1. Formulation and delivery of proteins and peptides: Design and development strategies
2. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease
3. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind
4. Development of poly-(D,L-lactide-co-glycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis
5. Potential applications and delivery strategies for bone morphogenetic proteins
6. Delivery of cytokines by liposomes: Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes
7. The latest developments in insulin injection devices
8. A comparison of the use of premixed insulin in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM. Is there a decreased risk of night hypoglycemia?
9. Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injections
10. A pharmacokinetic and tolerability evaluation of two continuous subcutaneous infusion systems compared to an oral controlled-release morphine
11. Evaluation of an implant that delivers leuprolide for one year for the palliative treatment of prostate cancer
12. Solution stability of salmon calcitonin at high concentration for delivery in an implantable system
13. Biomaterials in drug delivery and tissue engineering: One laboratory's experience
14. Sustained delivery of proteins for novel therapeutic agents
15. Development of microspheres for neurological disorders: From basics to clinical applications
16. Revisiting PLA/PLGA microspheres: An analysis of their potential in parenteral vaccination
17. Sustained release of human growth hormone from PLGA solution depots
18. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: Effect of various formulation variables
19. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate
20. New biodegradable polymers for injectable drug delivery systems
21. Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres
22. Branched biodegradable polyesters for parenteral drug delivery systems
23. Poly(ortho esters) - Their development and some recent applications
24. Intraarterial protein delivery via intimally-adherent bilayer hydrogels
25. Evaluation of SABER™ as a local delivery system for rhVEGF formulation design and in vitro assessment
26. DepoFoam technology: A vehicle for controlled delivery of protein and peptide drugs
27. Microstructure and release characteristics of the minipellet, a collagen-based drug delivery system for controlled release of protein drugs
28. Hyaluronic acid grafted with poly(ethylene glycol) as a novel peptide formulation
29. Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems
30. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys
31. Local drug delivery
32. Targeted drug delivery for brain cancer treatment
33. The ascent of pulmonary drug delivery
34. Delivery of peptide and non-peptide drugs through the respiratory tract
35. Pulmonary delivery of drugs for bone disorders
36. Effects of sodium glycocholate and protease inhibitors on permeability of TRH and insulin across rabbit trachea
37. Proteolytic enzymes as a limitation for pulmonary absorption of insulin: In vitro and in vivo investigations
38. Sustained release of insulin from insoluble inhaled particles
39. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler
40. Formulation of proteins for pulmonary delivery
41. Development of a new type nozzle and spray-drier for industrial production of fine powders
42. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect
43. Gelatin microspheres as a pulmonary delivery system: Evaluation of salmon calcitonin absorption
44. Transdermal drug delivery: Overcoming the skin's barrier function
45. Synergistic effect of low-frequency ultrasound and sodium lauryl sulfate on transdermal transport
46. Transdermal and transmucosal powdered drug delivery
47. Modulation of tight junctional permeability
48. Recent technological advances in oral drug delivery - A review
49. A mechanistic analysis of carrier-mediated oral delivery of protein therapeutics
50. The development of delivery agents that facilitate the oral absorption of macromolecular drugs
51. Polycarbophil-cysteine conjugates as platforms for oral polypeptide delivery system
52. Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake?